Vanguard Capital Management’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$178M Buy
18,804,937
+3,113,358
+20% +$24.9M ﹤0.01% 1177
2026
Q2
$137M Buy
15,691,579
+563,865
+4% +$4.27M ﹤0.01% 1373
2026
Q1
$116M Buy
+15,127,714
New +$104M ﹤0.01% 1390

Other funds holding IBRX

Vanguard Capital Management's IBRX Position: Q3 2026 in Review

Vanguard Capital Management increased its ImmunityBio (IBRX) stake by 20% in Q3 2026, buying an estimated $24.9M and bringing the position to 18,804,937 shares worth $178M. The position accounts for ﹤0.01% of the portfolio, ranked #1177.

Vanguard Capital Management first reported a position in IBRX in Q1 2026 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Vanguard Capital Management held 18,804,937 shares of ImmunityBio worth $178M as of Q3 2026.
  • Vanguard Capital Management bought 3,113,358 ImmunityBio shares in Q3 2026, an estimated $24.9M.
  • ImmunityBio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1177 holding.
  • Vanguard Capital Management first reported a position in ImmunityBio in Q1 2026 and has held it in 3 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.